Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Bugworks","sponsor":"University of Tokyo Edge Capital","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bugworks Raises US$7.5M From a Global Investment Syndicate to Combat the Global Challenge Posed by Deadly Bacterial Superbugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bugworks"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$14.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bharat Bio Consortium Gets $14m Grant for Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KindredBio Expands Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Centaur Pharmaceuticals"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech to Start Phase-1 Trials of Covid-19 Intranasal Vaccine in Feb-March","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"AIIMS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIIMS Delhi to Conduct Phase 2 of Bharat Biotech's Nasal Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"orgOrder":0,"company":"Bugworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bugworks Research Begins First in Human Phase 1 Study of BWC0977 to Treat Critical Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bugworks"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Orphan Drug Designation From US FDA for ZY-19489, A Novel Compound to Treat Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Zydus Lifesciences"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NTAGI May Soon Review Efficacy Data of India's First Intranasal Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bharat Biotech"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute to Produce Ebola Vaccine for Use in Uganda Outbreak","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Serum Institute of India"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Serum Institute of India

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Serum Institute to Produce Ebola Vaccine for Use in Uganda Outbreak

Details:

ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm. The vaccine will be administered intramuscularly (IM).

Lead Product(s): ChAdOx1 biEBOV

Therapeutic Area: Infections and Infectious Diseases Product Name: ChAdOx1 biEBOV

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: University of Oxford

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 17, 2022

ASK
US

Upload
your Pipeline Activity

Bharat Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

NTAGI May Soon Review Efficacy Data of India's First Intranasal Covid Vaccine

Details:

India's drug controller had in January this year given permission to Bharat Biotech to conduct standalone on its Covid-19 intranasal vaccine. The phase 3 trials of the intranasal vaccine candidate BBV154 (Chad SARS-COV-2) are underway and likely to be completed soon.

Lead Product(s): Chad SARS-COV-2

Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2022

ASK
US

Upload
your Pipeline Activity

Zydus Lifesciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Zydus Receives Orphan Drug Designation From US FDA for ZY-19489, A Novel Compound to Treat Malaria

Details:

Orphan drug designation is based on Phase I study of ZY19489, a novel antimalarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug-resistant strains.

Lead Product(s): ZY-19489

Therapeutic Area: Infections and Infectious Diseases Product Name: ZY-19489

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 16, 2021

ASK
US

Upload
your Pipeline Activity

Bugworks

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bugworks Research Begins First in Human Phase 1 Study of BWC0977 to Treat Critical Bacterial Infections

Details:

BWC0977 is a highly potent, intravenous broad-spectrum antibiotic with the potential for oral administration, for the treatment of serious multi drug resistant (MDR) gram-negative infections.

Lead Product(s): BWC0977

Therapeutic Area: Infections and Infectious Diseases Product Name: BWC0977

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 09, 2021

ASK
US

Upload
your Pipeline Activity

Bharat Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AIIMS Delhi to Conduct Phase 2 of Bharat Biotech's Nasal Vaccine Trials

Details:

Bharat Biotech's intranasal vaccine, BBV154, received regulatory approval for second phase trials in August. The trials will begin in a couple of weeks after permission is granted by the committee.

Lead Product(s): Chad SARS-COV-2

Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: AIIMS

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 09, 2021

ASK
US

Upload
your Pipeline Activity

Bharat Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bharat Biotech to Start Phase-1 Trials of Covid-19 Intranasal Vaccine in Feb-March

Details:

BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. The Phase-1 trials will be conducted in Saint Louis University's Vaccine and Treatment Evaluation Unit.

Lead Product(s): BBV154

Therapeutic Area: Infections and Infectious Diseases Product Name: BBV154

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

ASK
US

Upload
your Pipeline Activity

Centaur Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

KindredBio Expands Manufacturing Agreement with Vaxart

Details:

The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.

Lead Product(s): VXA-CoV2-1

Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Vaxart

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 07, 2020

ASK
US

Upload
your Pipeline Activity

Bharat Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bharat Bio Consortium Gets $14m Grant for Chikungunya Vaccine

Details:

CEPI will fund the consortium for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya. The partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial to be conducted by IVI.

Lead Product(s): BBV87

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $14.1 million Upfront Cash: Undisclosed

Deal Type: Funding May 03, 2020

ASK
US

Upload
your Pipeline Activity

Bugworks

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bugworks Raises US$7.5M From a Global Investment Syndicate to Combat the Global Challenge Posed by Deadly Bacterial Superbugs

Details:

This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.

Lead Product(s): GYROX-1

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: University of Tokyo Edge Capital

Deal Size: $7.5 million Upfront Cash: Undisclosed

Deal Type: Financing April 22, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY